At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
ARO-AATdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Open Label, Multi-dose, Phase 2 Study to Assess the Safety and Efficacy of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
In Brief
A Phase 2 clinical trial evaluating ARO-AAT for Alpha 1-Antitrypsin Deficiency. Completed, enrolled 16 participants across 4 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate the the safety and efficacy of the investigational product, fazirsiran (TAK-999, ARO-AAT), administered subcutaneously to patients with alpha-1 antitrypsin deficiency associated liver disease (AATD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlpha 1-Antitrypsin Deficiency
CountriesAustria, Germany, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartOct 2019
Primary CompletionApr 2022
Study CompletionDec 2023
TodayJul 2026
First PostedMay 10, 2019
Enrollment StartOct 31, 2019
Primary CompletionApr 28, 2022
Study CompletionDec 14, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 7.1 years ago
Interventions
ARO-AATdrug
solution for subcutaneous injection